Page last updated: 2024-10-22

alfuzosin and Idiopathic Parkinson Disease

alfuzosin has been researched along with Idiopathic Parkinson Disease in 1 studies

alfuzosin: structure given in first source

Research Excerpts

ExcerptRelevanceReference
" Additional dose-response analyses were carried out."1.62Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. ( Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Simmering, JE1
Welsh, MJ1
Liu, L1
Narayanan, NS1
Pottegård, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860]Phase 1/Phase 240 participants (Anticipated)Interventional2024-10-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for alfuzosin and Idiopathic Parkinson Disease

ArticleYear
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
    JAMA neurology, 2021, 04-01, Volume: 78, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases,

2021